Over the two years of planning and executing the CBDynamics project, we deeply explored the business and industrial perspectives of the cannabidiol market, as well as the expanding field of synthetic biology. In 2024, we began a series of studies on consumption trends and the growing demand for cannabidiol, with the goal of assessing how the market views our product and identifying growth opportunities. Based on these analyses, we structured a detailed proposed business model that not only outlines our strategic vision for the production of synthetic cannabidiol but also focuses on distribution channels and the production methodologies we will adopt.

To ensure our plan was effective and aligned with industry needs, we sought the support of Mona das Neves Oliveira, CEO of BioLinker, a brazilian synthetic biology startup that uses genetic engineering tools for recombinant protein production. Throughout this process, in addition to absorbing valuable feedback, we also expanded our understanding of critical elements of solid business planning, such as marketing strategies, client identification and acquisition, and a critical analysis of the project and team performance.

In summary, the Business Model was structured with the purpose of not only understanding market demands but also studying the most efficient and sustainable ways of producing and distributing synthetic cannabidiol, ensuring that our project is prepared to meet the expectations of both the market and regulators, while also expanding the social and economic impact of our innovations.